Canakinumab

From Wikipedia, the free encyclopedia

Canakinumab?
Therapeutic monoclonal antibody
Source Human
Target IL-1β
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula  ?
Mol. mass  ?
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes Intravenous, subcutaneous

Canakinumab (INN, codenamed ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It is being developed by Novartis for the treatment of rheumatoid arthritis. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease[1] and in phase III studies for Muckle-Wells syndrome, a rare genetic disease.[2][3]

[edit] References

  1. ^ Yasothan U, Kar S (2008). "Therapies for COPD" ([dead link] – Scholar search). Nat Rev Drug Discov 7: 285. doi:10.1038/nrd2533. 
  2. ^ Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome. ClinicalTrials.gov. U.S. National Institutes of Health (January 8, 2008). Retrieved on 2008-03-26.
  3. ^ Ferrer E, Moral MA, Bozzo J (2007). "Muckle-Wells syndrome". Drugs Fut 32 (19): 919. doi:10.1358/dof.2007.032.10.1143492. 
Pills  This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Human monoclonal antibodies ("-u-")
"-limu-" (immune system)
"-kinu-" (interleukin as target)
Canakinumab
"-tumu-" (cancer immunotherapy)
"-osu-" (bone)
"-mulu-" (musculoskeletal)
"-fungu-" (fungal)
"-viru-" (viral)
"-bacu-" (bacterial)